SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Robert F. Kennedy Jr., President Donald Trump's nominee to be secretary of the Health and Human Services Department, testifies in front of the Senate Finance Committee on January 29, 2025.
(Photo: Nathan Posner/Anadolu via Getty Images)
RFK Jr Pressed on Whether He and Trump Will 'Cave to Big Pharma' on Medicare Drug Prices
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sen. Bernie Sanders asked Kennedy during his second confirmation hearing.
Jan 30, 2025
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."
We are at a crossroads
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
bernie sandersbig pharmacorporate powerdonald trumpdrug pricesinflation reduction actus senaterfk jr
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.
To inform. To inspire. To ignite change for the common good.
News & Opinion
Trending
Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit
Privacy Policy